美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Parabilis Medicines

36.88

+1.163.25%

盤前：36.880.00000.00%04:18 EDT

成交量：97.11萬

成交額：3,622.11萬

市值：45.73億

市盈率：-1.57

高：38.92

開：36.19

低：35.37

收：35.72

52周最高：41.49

52周最低：24.51

股本：1.24億

流通股本：3,350.00萬

量比：1.96

換手率：2.90%

股息：- -

股息率：- -

每股收益(TTM):-23.4458

每股收益(LYR):-60.0402

淨資產收益率：--

總資產收益率：--

市淨率：4.36

市盈率(LYR):-0.61

資料載入中...

總覽公司新聞資訊公告

Parabilis Medicines任命資深藥物開發專家Craig L. Tendler博士為董事會成員

Parabilis Medicines任命資深藥物開發專家Craig L. Tendler醫學博士為董事會成員

Parabilis Medicines 第二季度末手握11億美元現金及等價物，預計資金可支撐運營至2030年

美國銀行全球研究首次覆蓋Parabilis Medicines，給予買入評級及45美元目標價

美國研究綜述-東西銀行、第一公民銀行控股公司、UMB

Parabilis Medicines宣佈完成規模擴大的首次公開募股，承銷商全額行使超額配售權

異動解讀｜Parabilis Medicines盤中上漲49.15%，IPO首日獲10倍超額認購大幅高開

熱門話題-藥物開發商Parabilis Medicines在納斯達克上市首日股價大漲

異動解讀 | 美股IPO上市受熱捧，Parabilis Medicines盤中大漲66.75%

美股異動 | Parabilis Medicines(PBLS.US)登陸美股市場開盤後股價升逾44%

癌症肽療法新星Parabilis(PBLS.US)超區間定價IPO，獲10倍超額認購最終募資7.45億美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/PBLS/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PBLS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBLS\",,,,,undefined,":{"symbol":"PBLS","market":"US","secType":"STK","nameCN":"Parabilis Medicines","latestPrice":36.88,"timestamp":1789588800000,"preClose":35.72,"halted":0,"volume":971054,"hourTrading":{"tag":"盘前","latestPrice":36.88,"preClose":36.88,"latestTime":"04:18 EDT","volume":200,"amount":7376.000000000001,"timestamp":1789633127651,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03247480403135509,"floatShares":33500000,"shares":124000000,"eps":-23.44581,"marketStatus":"盤前交易","change":1.16,"latestTime":"09-17 04:37:59 EDT","open":36.19,"high":38.915,"low":35.3709,"amount":36221106.580064,"amplitude":0.099219,"askPrice":43.42,"askSize":100,"bidPrice":33.38,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-23.44581,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"listingDate":1781064000000,"exchange":"NASDAQ","adjPreClose":36.88,"preHourTrading":{"tag":"盘前","latestPrice":36.88,"preClose":36.88,"latestTime":"04:18 EDT","volume":200,"amount":7376.000000000001,"timestamp":1789633127651,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":36.88,"preClose":36.88,"latestTime":"19:56 EDT","volume":3011,"amount":111080.69,"timestamp":1789602997330,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.9613892409907747,"impliedVol":0.6935,"impliedVolPercentile":0.6744},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBLS\",,,,,undefined,":{"symbol":"PBLS","floatShares":33500000,"roa":"--","roe":"--","lyrEps":-60.040199,"volumeRatio":1.9613892409907747,"shares":124000000,"dividePrice":0,"high":38.915,"amplitude":0.099219,"preClose":35.72,"low":35.3709,"week52Low":24.51,"pbRate":"4.36","psRate":"30899.46","week52High":41.4899,"institutionHeld":0,"latestPrice":36.88,"eps":-23.44581,"divideRate":0,"volume":971054,"delay":0,"ttmEps":-23.44581,"open":36.19,"prevYearClose":20,"prevWeekClose":36.88,"prevMonthClose":39.01,"prevQuarterClose":27.37,"fiveDayClose":38.76,"twentyDayClose":39.35,"sixtyDayClose":27.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBLS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"PBLS","fiscalQuarterEnding":"2026/06","expectedEps":-0.16,"name":null,"time":"盤前","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-2.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBLS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBLS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1786766400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PBLS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PBLS","date":"2026-09-16","current":-1.572989,"percent":0.560606,"low":-31.159897,"twenty":-28.655782,"median":-26.470503,"eighty":-23.53667,"high":-15.535256,"avg":-26.153496,"sd":2.893996,"marketCap":4412607332},"quantilePoints":[{"date":"2026-06-12","current":-23.423744,"twenty":-24.021896,"median":-23.423744,"eighty":-18.690651,"marketCap":3580998591},{"date":"2026-06-18","current":-21.681158,"twenty":-23.280127,"median":-22.147598,"eighty":-21.001488,"marketCap":3314593719},{"date":"2026-06-26","current":-21.956025,"twenty":-22.933884,"median":-22.426629,"eighty":-21.561216,"marketCap":3356615076},{"date":"2026-07-02","current":-23.122126,"twenty":-23.423744,"median":-22.77646,"eighty":-21.681158,"marketCap":3534887500},{"date":"2026-07-10","current":-25.287743,"twenty":-24.420664,"median":-22.938881,"eighty":-21.956025,"marketCap":3865964860},{"date":"2026-07-17","current":-24.204934,"twenty":-24.912925,"median":-23.706058,"eighty":-22.147598,"marketCap":3700426180},{"date":"2026-07-24","current":-27.328421,"twenty":-25.279414,"median":-24.204934,"eighty":-22.705661,"marketCap":4177941603},{"date":"2026-07-31","current":-26.886968,"twenty":-25.665893,"median":-24.321545,"eighty":-22.738979,"marketCap":4110452756},{"date":"2026-08-07","current":-29.635636,"twenty":-26.527142,"median":-24.625564,"eighty":-22.753971,"marketCap":4530666328},{"date":"2026-08-14","current":-29.710599,"twenty":-28.289622,"median":-24.912925,"eighty":-22.788954,"marketCap":4542126698},{"date":"2026-08-21","current":-28.671719,"twenty":-28.53843,"median":-25.283578,"eighty":-22.890572,"marketCap":4889445639},{"date":"2026-08-28","current":-28.461644,"twenty":-28.506557,"median":-25.662561,"eighty":-22.933884,"marketCap":4853620999},{"date":"2026-09-04","current":-29.519266,"twenty":-28.607972,"median":-26.20813,"eighty":-23.085477,"marketCap":5033979530},{"date":"2026-09-11","current":-26.310178,"twenty":-28.726773,"median":-26.487161,"eighty":-23.303097,"marketCap":4486727276},{"date":"2026-09-16","current":-25.875539,"twenty":-28.655782,"median":-26.470503,"eighty":-23.53667,"marketCap":4412607332}],"updateTime":1789634279082},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBLS\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1121669089","title":"Parabilis Medicines任命資深藥物開發專家Craig L. Tendler博士為董事會成員","url":"https://stock-news.laohu8.com/highlight/detail?id=1121669089","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121669089?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 19:04","pubTimestamp":1787655884,"startTime":"0","endTime":"0","summary":"马萨诸塞州剑桥，2026年8月25日——Parabilis Medicines今日正式宣布，Craig L. Tendler博士将加入公司董事会。Tendler博士的职业生涯亮点颇多。此前，他已担任Parabilis Medicines的科学顾问，此番履新后，他将同时肩负这两个重要角色。\"我们非常高兴欢迎Craig加入Parabilis董事会。在这个关键节点加入Parabilis董事会，我倍感欣喜。目前，Tendler博士还担任TuHURA Biosciences和Predicta Biosciences的董事会成员，并为多家生物技术公司提供科学顾问服务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4605","TM","LU1720051017.SGD","LU2298322129.HKD","LU1861215975.USD","LU2357305700.SGD","LU2360107325.USD","COAL","LU1854104046.USD","BK4099","LU1983260115.SGD","HCC","LU1861214812.USD","BK4022","LU1854103824.USD","LU1978683503.SGD","ONG","IE00BD6J9T35.USD","BK4604","IE00BZ199S13.USD","ACP","BK4555","LU1548497426.USD","LU1861220033.SGD","LU0124384867.USD","LU1861219969.SGD","ON","BK4512","LU1720051108.HKD","ONX","LU0724618433.USD","BK4006","BK4588","IE00BFMHRM44.USD","BK4141","R","BK4139","BK4585","BK4232","PBLS","LU0348723411.USD","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143247197","title":"Parabilis Medicines任命資深藥物開發專家Craig L. Tendler醫學博士為董事會成員","url":"https://stock-news.laohu8.com/highlight/detail?id=1143247197","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143247197?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 19:01","pubTimestamp":1787655676,"startTime":"0","endTime":"0","summary":"Parabilis Medicines宣布，已正式任命在药物开发领域建树颇丰的Craig L. Tendler医学博士加入公司董事会。Tendler博士拥有数十年的行业经验，其职业生涯横跨多个治疗领域，并在推动创新疗法从早期研究走向商业化方面拥有卓越记录。此次人事任命，被视作公司强化战略领导力的关键一步，旨在加速其管线资产的推进与拓展。Parabilis Medicines方面表示，Tendler博士的深厚专业知识和广泛行业网络，将为公司在复杂多变的生物制药环境中导航提供重要支持。随着Tendler博士的加入，董事会将更加多元，决策视角亦更为丰富，为公司下一阶段的发展注入强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110375422","title":"Parabilis Medicines 第二季度末手握11億美元現金及等價物，預計資金可支撐運營至2030年","url":"https://stock-news.laohu8.com/highlight/detail?id=1110375422","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110375422?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 19:07","pubTimestamp":1786619229,"startTime":"0","endTime":"0","summary":"Parabilis Medicines 在第二季度结束时，所持有的现金、现金等价物以及有价证券总额高达11亿美元。这笔充裕的资金储备，预计将足以支撑公司的运营活动，直至2030年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146739009","title":"美國銀行全球研究首次覆蓋Parabilis Medicines，給予買入評級及45美元目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=1146739009","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146739009?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 19:39","pubTimestamp":1783337956,"startTime":"0","endTime":"0","summary":"美国银行全球研究已开始对生物制药公司Parabilis Medicines进行覆盖分析，并首次给予其股票“买入”评级。该机构为Parabilis Medicines设定了45.00美元的目标股价，显示出对其未来增长潜力的积极预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649644013","title":"美國研究綜述-東西銀行、第一公民銀行控股公司、UMB","url":"https://stock-news.laohu8.com/highlight/detail?id=2649644013","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649644013?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 16:22","pubTimestamp":1783326173,"startTime":"0","endTime":"0","summary":"美国研究综述-东西银行、第一公民银行控股公司、UMB路透7月6日-周一，华尔街证券分析师下调了多家在美国上市公司的评级和目标股价，其中包括东西银行、第一公民银行控股公司和UMB金融公司。股票条目按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nL4S4380GO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HBAN","AGMI","GILD","ADP","IQV","NEMG","PJP","ZION","QABA","FTXH","NEM","ABBV","BIIB","USB","UNHW","MRK","PBLS","IHE","PFE","MEDI","BBH","SOC","FRBT","EKG","IBB","CCB","DLTR","UNH","UNHG","OZK","PAWZ","CFR","EWBC","EROC","FCNCA","DFNL","FLG","IHF","RGLD","UMBF","AGNG","JNJ","REGN","WTFC","CBSH","ZTS","PNFP","XLV","CVS","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189403882","title":"Parabilis Medicines宣佈完成規模擴大的首次公開募股，承銷商全額行使超額配售權","url":"https://stock-news.laohu8.com/highlight/detail?id=1189403882","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189403882?lang=zh_tw&edition=fundamental","pubTime":"2026-06-12 04:06","pubTimestamp":1781208398,"startTime":"0","endTime":"0","summary":"Parabilis Medicines宣布，其规模扩大的首次公开募股（IPO）已正式完成。此次发行中，承销商全额行使了购买额外股份的选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120727250","title":"異動解讀｜Parabilis Medicines盤中上漲49.15%，IPO首日獲10倍超額認購大幅高開","url":"https://stock-news.laohu8.com/highlight/detail?id=1120727250","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120727250?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 02:03","pubTimestamp":1781114598,"startTime":"0","endTime":"0","summary":"6月10日，Parabilis Medicines盘中上涨49.15%，报29.83美元/股，成交额1.01亿美元。消息面上，公司当日完成美股IPO并挂牌上市，发行价定为每股20美元，高于此前17-19美元的推介区间，IPO认购需求达可供股份数的约10倍。本次IPO发行3350万股，募资约6.70亿美元；同时再生元制药以每股18美元认购约7500万美元股份，合计筹资近7.45亿美元。Parabilis Medicines是一家临床阶段生物制药公司，专注于开发用于癌症治疗的工程化肽疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642478308","title":"熱門話題-藥物開發商Parabilis Medicines在納斯達克上市首日股價大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2642478308","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642478308?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 01:20","pubTimestamp":1781112027,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nL4S42I1G5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","LU1974910355.USD","LU0823416689.USD","PBLS","LU0889565916.HKD","BK4588","BK4539","LU0114720955.EUR","LU0320765992.SGD","LU1917777945.USD","LU0058720904.USD","LU2362541513.USD","BK4139","REGN","LU2237438978.USD","LU0109394709.USD","LU2023250504.SGD","LU2362541273.HKD","LU0882574055.USD","LU0289739699.SGD","LU2468319806.SGD","LU0823434583.USD","NUVL","LU2089984988.USD","LU2362540622.SGD","BK4585","LU0823434740.USD","LU2106854487.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104824154","title":"異動解讀 | 美股IPO上市受熱捧，Parabilis Medicines盤中大漲66.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104824154","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104824154?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 01:12","pubTimestamp":1781111553,"startTime":"0","endTime":"0","summary":"生物科技公司Parabilis Medicines  今日盘中股价大幅飙升66.75%，成为市场焦点。Parabilis Medicines成立于2015年，专注于开发针对多种癌症及罕见肿瘤的治疗方案，此次IPO募集资金将主要用于推进其最领先的候选药物zolucatetide进入更后期的临床试验阶段，这增强了投资者对公司未来发展的信心。市场分析认为，尽管公司目前处于亏损状态，但其在癌症治疗领域的专业性和IPO带来的资金注入，为其后续的研发和商业化提供了关键支持，从而推动了股价的积极表现。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642478833","title":"美股異動 | Parabilis Medicines(PBLS.US)登陸美股市場 開盤後股價升逾44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642478833","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642478833?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 00:00","pubTimestamp":1781107200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，聚焦癌症治疗的美国生物科技公司Parabilis Medicines(PBLS.US)登陆美股市场，开盘股价走高，截至发稿，该股涨44.35%，报28.87美元。IPO价格为20美元。Parabilis成立于2015年，专注于开发用于多种癌症及罕见肿瘤的治疗方案。公司拟将IPO募集资金用于推进其最领先候选药物zolucatetide进入更后期临床试验阶段。截至2025财年年末，Parabilis净亏损1.459亿美元，期末现金及现金等价物2,770万美元;前一财年净亏损为1.179亿美元，现金为4,730万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | Parabilis Medicines(PBLS.US)登陆美股市场 开盘后股价涨超44%","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642414058","title":"癌症肽療法新星Parabilis(PBLS.US)超區間定價IPO，獲10倍超額認購 最終募資7.45億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642414058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642414058?lang=zh_tw&edition=fundamental","pubTime":"2026-06-10 11:30","pubTimestamp":1781062200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，聚焦癌症治疗的美国生物科技公司Parabilis Medicines完成了一项规模上调的美股IPO，发行价定在推介区间之上，叠加同步进行的私募配售，合计筹资近 7.45亿美元。在本次周二上调规模前，IPO认购需求已达可供股份数的约10倍。文件显示，截至 2025财年年末，Parabilis 净亏损 1.459亿美元，期末现金及现金等价物 2,770万美元;前一财年净亏损为 1.179亿美元，现金为 4,730万美元。Parabilis 成立于 2015年，专注于开发用于多种癌症及罕见肿瘤的治疗方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","PBLS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}